BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33544320)

  • 21. Incidental Detection of Oxyphilic Papillary Thyroid Carcinoma by 18F-Fluorocholine PET/CT.
    Lalire P; Zalzali M; Garbar C; Bruna-Muraille C; Morland D
    Clin Nucl Med; 2016 Jun; 41(6):512-3. PubMed ID: 26914574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
    Mucha SA; Kunert-Radek J; Pomorski L
    Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
    Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
    Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative F-18 fluorocholine PET/CT for the detection of hyperfunctioning parathyroid glands in patients with secondary or tertiary hyperparathyroidism: comparison with Tc-99m sestamibi scan and neck ultrasound.
    Chen YH; Chen HT; Lee MC; Liu SH; Wang LY; Lue KH; Chan SC
    Ann Nucl Med; 2020 Aug; 34(8):527-537. PubMed ID: 32436180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
    Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.
    Rubello D; Rampin L; Nanni C; Banti E; Ferdeghini M; Fanti S; Al-Nahhas A; Gross MD
    Eur J Surg Oncol; 2008 May; 34(5):581-6. PubMed ID: 17892923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
    Chen SW; Chen YK
    World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases.
    Castroneves LA; Coura Filho G; de Freitas RMC; Salles R; Moyses RA; Lopez RVM; Pereira MAA; Tavares MR; Jorge AAL; Buchpiguel CA; Hoff AO
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3250-3259. PubMed ID: 29846642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to
    Puhr-Westerheide D; Cyran CC; Sargsyan-Bergmann J; Todica A; Gildehaus FJ; Kunz WG; Stahl R; Spitzweg C; Ricke J; Kazmierczak PM
    Cancer Imaging; 2019 Nov; 19(1):73. PubMed ID: 31727170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical relevance of
    Saponjski J; Macut D; Saranovic DS; Radovic B; Artiko V
    Radiol Oncol; 2020 Nov; 55(1):18-25. PubMed ID: 33885241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET.
    Sesti A; Mayerhoefer M; Weber M; Anner P; Wadsak W; Dudczak R; Haug A; Karanikas G
    Anticancer Res; 2014 Nov; 34(11):6647-54. PubMed ID: 25368270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan.
    Tong AK; Zhang ZX; Zaheer S; Yan XS
    Clin Imaging; 2016; 40(3):486-91. PubMed ID: 27133692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
    Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine.
    Treglia G; Rufini V; Piccardo A; Imperiale A
    Semin Nucl Med; 2023 Jul; 53(4):481-489. PubMed ID: 36702731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of
    Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
    Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytology versus calcitonin assay in fine-needle aspiration biopsy wash-out fluid (FNAB-CT) in diagnosis of medullary thyroid microcarcinoma.
    Liu Z; Zhou W; Han R; Zhou W; Zhang J; Li H; Wan Z; Jin Y; Shen L; Zhou Y; Wang S; Chen X; Ye L
    Endocrine; 2021 Nov; 74(2):340-348. PubMed ID: 34028648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma: A Network Meta-analysis.
    Lee SW; Shim SR; Jeong SY; Kim SJ
    Clin Nucl Med; 2020 May; 45(5):341-348. PubMed ID: 32049723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.